Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shahrooz Eshaghian

Showing results (1-10 of 19) with videos related to

Pageof 2
Sort By:
Current Opinion in Supportive and Palliative Care|August 9, 2012
Multiple myeloma: improved outcomes with new therapeutic approachesShahrooz Eshaghian, James R Berenson
International Journal of Hematology|November 1, 2011
Glomerular hemophagocytic macrophages in a patient with proteinuria and clinical and laboratory features of hemophagocytic lymphohistiocytosis (HLH)Ling Cao, William Dean Wallace, Shahrooz Eshaghian, et al.
Open Medicine (Warsaw, Poland)|July 22, 2017
Impact of Chromosomal Rearrangement upon DNA Methylation Patterns in LeukemiaHyang-Min Byun, Shahrooz Eshaghian, Dan Douer, et al.
Journal of Medical Virology|March 21, 2012
Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis in Los Angeles CountyTheodoros Kelesidis, Romney Humphries, Dawn Terashita, et al.
Targeted Oncology|September 8, 2023
Clinical Outcomes and Serum B-Cell Maturation Antigen Levels in a Real-World Unselected Population of Newly Diagnosed Multiple Myeloma PatientsScott Jew, Sean Bujarski, Bernard Regidor, et al.
Clinical Infection in Practice|December 15, 2021
Severe breakthrough COVID-19 with a heavily mutated variant in a multiple myeloma patient 10 weeks after vaccinationSamuel D Stampfer, Marissa-Skye Goldwater, Sean Bujarski, et al.
Leukemia & Lymphoma|November 25, 2021
A phase 2 trial of the efficacy and safety of elotuzumab in combination with pomalidomide, carfilzomib and dexamethasone for high-risk relapsed/refractory multiple myelomaDavid Yashar, Tanya M Spektor, Daisy Martinez, et al.
Cancer Reports (Hoboken, N.J.)|March 9, 2023
Loss of anti-spike antibodies following mRNA vaccination for COVID-19 among patients with multiple myelomaSamuel D Stampfer, Sean Bujarski, Marissa-Skye Goldwater, et al.
Annals of Hematology|December 10, 2016
Outcomes of multiple myeloma patients receiving bortezomib, lenalidomide, and carfilzomibAriana Berenson, Suzie Vardanyan, Michael David, et al.
Annals of Hematology|December 4, 2016
Improved clinical outcomes for multiple myeloma patients treated at a single specialty clinicAriana Berenson, Suzie Vardanyan, Michael David, et al.
Pageof 2

Showing results (1-10 of 19) with videos related to

Sort By:
Pageof 2
Current Opinion in Supportive and Palliative Care|August 9, 2012
Multiple myeloma: improved outcomes with new therapeutic approachesShahrooz Eshaghian, James R Berenson
International Journal of Hematology|November 1, 2011
Glomerular hemophagocytic macrophages in a patient with proteinuria and clinical and laboratory features of hemophagocytic lymphohistiocytosis (HLH)Ling Cao, William Dean Wallace, Shahrooz Eshaghian, et al.
Open Medicine (Warsaw, Poland)|July 22, 2017
Impact of Chromosomal Rearrangement upon DNA Methylation Patterns in LeukemiaHyang-Min Byun, Shahrooz Eshaghian, Dan Douer, et al.
Journal of Medical Virology|March 21, 2012
Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis in Los Angeles CountyTheodoros Kelesidis, Romney Humphries, Dawn Terashita, et al.
Targeted Oncology|September 8, 2023
Clinical Outcomes and Serum B-Cell Maturation Antigen Levels in a Real-World Unselected Population of Newly Diagnosed Multiple Myeloma PatientsScott Jew, Sean Bujarski, Bernard Regidor, et al.
Clinical Infection in Practice|December 15, 2021
Severe breakthrough COVID-19 with a heavily mutated variant in a multiple myeloma patient 10 weeks after vaccinationSamuel D Stampfer, Marissa-Skye Goldwater, Sean Bujarski, et al.
Leukemia & Lymphoma|November 25, 2021
A phase 2 trial of the efficacy and safety of elotuzumab in combination with pomalidomide, carfilzomib and dexamethasone for high-risk relapsed/refractory multiple myelomaDavid Yashar, Tanya M Spektor, Daisy Martinez, et al.
Cancer Reports (Hoboken, N.J.)|March 9, 2023
Loss of anti-spike antibodies following mRNA vaccination for COVID-19 among patients with multiple myelomaSamuel D Stampfer, Sean Bujarski, Marissa-Skye Goldwater, et al.
Annals of Hematology|December 10, 2016
Outcomes of multiple myeloma patients receiving bortezomib, lenalidomide, and carfilzomibAriana Berenson, Suzie Vardanyan, Michael David, et al.
Annals of Hematology|December 4, 2016
Improved clinical outcomes for multiple myeloma patients treated at a single specialty clinicAriana Berenson, Suzie Vardanyan, Michael David, et al.
Pageof 2